Skip to main content
. 2020 Oct 6;30(2):425–436. doi: 10.1007/s11136-020-02655-7

Table 2.

Baseline participants’ demographics and medical data in each group

Total sample (N = 95) Intervention group (N = 48) WLCG (N = 47)
Demographics
 Age (years)
  Mean (SD) 53.85 (11.91) 51.65 (12.54) 56.11 (10.90)
  Range 24–78 24–78 30–78
 Gender, N (%)
  Women 95 (100) 48 (100) 47 (100)
 Marital status, N (%)
  Single 6 (6.32) 3 (6.25) 3 (6.38)
  Married/living with partner 63 (66.32) 35 (72.92) 28 (59.57)
  Divorced/separated/widowed 15 (15.79) 5 (10.42) 10 (21.28)
  In a relationship but not living together 11 (11.58) 5 (10.42) 6 (12.77)
 Cultural origin, N (%)
  Western Europe 92 (96.84) 45 (93.75) 47 (100)
  Eastern Europe 3 (3.16) 3 (6.25) 0 (0.00)
 Education level, N (%)
  Elementary school or less 1 (1.05) 0 (0.00) 1 (2.13)
  Lower secondary school 8 (8.42) 3 (6.25) 5 (10.64)
  Upper secondary school 25 (26.32) 14 (29.17) 11 (23.40)
  Bachelor’s degree 38 (40.00) 19 (39.58) 19 (40.43)
  Master’s degree 20 (21.05) 11 (22.92) 9 (19.15)
  Post-graduate 3 (3.16) 1 (2.08) 2 (4.26)
 Employment status, N (%)
  Employed full time 7 (7.37) 4 (8.33) 3 (6.38)
  Employed part time 21 (22.11) 9 (18.75) 12 (25.53)
  Incapacity of work/invalidity 37 (38.95) 22 (45.83) 15 (31.91)
  Unemployed/student/housewife/house-husband/retired/other 30 (31.58) 13 (27.08) 17 (36.17)
 Children, N (%)
  Yes 82 (86.32) 40 (83.33) 42 (89.36)
  No 13 (13.68) 8 (16.67) 5 (10.64)
Patient medical history
 Cancer diagnosis, N (%)
  Breast cancer 75 (78.94) 38 (79.17) 37 (78.72)
  Others 20 (21.06) 10 (20.83) 10 (21.28)
   Digestive (stomach, peritoneum, pancreas) 5 (5.26) 3 (6.25) 2 (4.26)
   Hematological cancer (lymphoma, leukemia) 4 (4.22) 3 (6.25) 1 (2.13)
   Gynecological cancer (cervix, ovaries) 4 (4.22) 3 (6.25) 1 (2.13)
   Skin 2 (2.11) 0 (0.00) 2 (4.26)
   Thyroid 2 (2.11) 0 (0.00) 2 (4.26)
   Ear/nose/throat 1 (1.05) 0 (0.00) 1 (2.13)
   Lung 1 (1.05) 1 (2.08) 0 (0.00)
   Brain 1 (1.05) 0 (0.00) 1 (2.13)
 Time since diagnosis (months)
  Mean (SD) 10.65 (8.69) 9.94 (5.13) 11.38 (11.25)
  Range 1–72 2–24 1–72
 Surgery, N (%)
  Yes 92 (96.84) 46 (95.83) 46 (97.87)
  No 3 (3.16) 2 (4.17) 1 (2.13)
 Chemotherapy (CT), N (%)
  Yes 52 (54.74) 29 (60.42) 23 (48.94)
  No 43 (45.26) 19 (39.58) 24 (51.06)
 Radiation therapy (RT), N (%)
  Yes 70 (73.68) 35 (72.92) 35 (74.47)
  No 25 (26.32) 13 (27.08) 12 (25.53)
 Hormonal therapy (HT), N (%)
  Yes 60 (63.16) 30 (62.50) 30 (63.83)
  No 35 (36.84) 18 (37.50) 17 (36.17)
 Other treatment, N (%)
  Yes 15 (15.79) 9 (18.75) 6 (12.77)
  No 80 (84.21) 39 (81.25) 41 (87.23)
 History of cancer, N (%)
  Yes 18 (18.95) 8 (16.67) 10 (21.28)
  No 77 (81.05) 40 (83.33) 37 (78.72)
 Other chronic health problem, N (%)
  Yes 55 (57.89) 27 (56.25) 28 (59.57)
  No 40 (42.11) 21 (43.75) 19 (40.43)
 Consumption of psychotropic during the study, N (%)
  Yes 50 (52.63) 27 (56.25) 23 (48.94)
  No 45 (47.37) 21 (43.75) 24 (51.06)